BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16269859)

  • 21. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
    Yoshida D; Koketshu K; Nomura R; Teramoto A
    J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 entry inhibitors: an overview.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Wagstaff AJ
    Drugs; 2009; 69(3):319-26. PubMed ID: 19275275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCR4 mediates the proliferation of glioblastoma progenitor cells.
    Ehtesham M; Mapara KY; Stevenson CB; Thompson RC
    Cancer Lett; 2009 Feb; 274(2):305-12. PubMed ID: 19008040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
    Ngo HT; Leleu X; Lee J; Jia X; Melhem M; Runnels J; Moreau AS; Burwick N; Azab AK; Roccaro A; Azab F; Sacco A; Farag M; Sackstein R; Ghobrial IM
    Blood; 2008 Jul; 112(1):150-8. PubMed ID: 18448868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.
    Cao YJ; Flexner CW; Dunaway S; Park JG; Klingman K; Wiggins I; Conley J; Radebaugh C; Kashuba AD; MacFarland R; Becker S; Hendrix CW
    Antimicrob Agents Chemother; 2008 May; 52(5):1630-4. PubMed ID: 18285477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.
    Kawai T; Choi U; Cardwell L; DeRavin SS; Naumann N; Whiting-Theobald NL; Linton GF; Moon J; Murphy PM; Malech HL
    Blood; 2007 Jan; 109(1):78-84. PubMed ID: 16946301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
    Pusic I; DiPersio JF
    Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
    Flomenberg N; DiPersio J; Calandra G
    Acta Haematol; 2005; 114(4):198-205. PubMed ID: 16269859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
    Flomenberg N; Devine SM; Dipersio JF; Liesveld JL; McCarty JM; Rowley SD; Vesole DH; Badel K; Calandra G
    Blood; 2005 Sep; 106(5):1867-74. PubMed ID: 15890685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis.
    Broxmeyer HE; Hangoc G; Cooper S; Campbell T; Ito S; Mantel C
    Ann N Y Acad Sci; 2007 Jun; 1106():1-19. PubMed ID: 17360804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
    Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
    J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
    Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
    Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined effects of hematopoietic progenitor cell mobilization from bone marrow by granulocyte colony stimulating factor and AMD3100 and chemotaxis into the brain using stromal cell-derived factor-1α in an Alzheimer's disease mouse model.
    Shin JW; Lee JK; Lee JE; Min WK; Schuchman EH; Jin HK; Bae JS
    Stem Cells; 2011 Jul; 29(7):1075-89. PubMed ID: 21608078
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.